Oxymetazoline hydrochloride is a Small Molecule owned by RVL Pharmaceuticals, and is involved in 6 clinical trials, of which 4 were completed, and 2 are ongoing.

Oxymetazoline hydrochloride is an alpha-1A adrenergic receptor agonist. By agonizing alpha(1)-adrenoceptor the drug causes stimulation and the contraction of the upper eyelid tarsal smooth muscle (Mueller's muscle) and opening of the eye.

The revenue for Oxymetazoline hydrochloride is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Oxymetazoline hydrochloride NPV Report.

Oxymetazoline hydrochloride was originated by Voom and is currently owned by RVL Pharmaceuticals. Santen Pharmaceutical is the other company associated in development or marketing of Oxymetazoline hydrochloride.

Oxymetazoline hydrochloride Overview

Oxymetazoline Hydrochloride (Upneeq) is an imidazole derivative with a direct acting sympathomimetic property. It is formulated as solution for ophthalmic route of administration. Upneeq is indicated for the treatment of acquired blepharoptosis in adults.

It was also under development for unspecified indications.

Santen Pharmaceutical Overview

Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.

The company reported revenues of (Yen) JPY266,257 million for the fiscal year ended March 2022 (FY2022), an increase of 6.7% over FY2021. In FY2022, the company’s operating margin was 14%, compared to an operating margin of 4.9% in FY2021. In FY2022, the company recorded a net margin of 10.2%, compared to a net margin of 3.7% in FY2021. The company reported revenues of JPY63,382 million for the second quarter ended September 2022, a decrease of 3.3% over the previous quarter.

Quick View – Oxymetazoline hydrochloride

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Oxymetazoline hydrochloride
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
  • Undisclosed
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.